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Human mitochondrial tyrosyl-tRNA synthetase and a truncated version with its
C-terminal S4-like domain deleted were purified and crystallized. Only the
truncated version, which is active in tyrosine activation and Escherichia coli
tRNATyr charging, yielded crystals suitable for structure determination. These
tetragonal crystals, belonging to space group P43212, were obtained in the
presence of PEG 4000 as a crystallizing agent and diffracted X-rays to 2.7 A˚
resolution. Complete data sets could be collected and led to structure solution
by molecular replacement.
1. Introduction
Aminoacyl-tRNA synthetases (aaRSs) are ancient enzymes that
ensure the correct attachment of amino acids on tRNA 30 ends. Each
amino acid has its specific synthetase; there are therefore 20 aaRSs in
nature, divided into two classes of ten based on structural and
functional features of their catalytic domain (Cusack et al., 1990;
Eriani et al., 1990). Tyrosyl-tRNA synthetases (TyrRSs) are modular
proteins that belong to the first class of synthetases, but have dimeric
organization and a class II mode of tRNA recognition (Yaremchuk et
al., 2002). TyrRS from Bacillus stearothermophilus was the first
synthetase to have its structure solved (Bhat et al., 1982) and at
present TyrRSs, with structures of representatives of the three
kingdoms of life (Bedouelle, 2005) and even from the mimivirus
infecting the protist Acanthamoeba polyphaga (Abergel et al., 2005),
are among the best-known aaRSs (Fig. 1). However, many features
related to the function, phylogeny and structure of this family of
enzymes remain to be deciphered. As far as function is concerned,
TyrRSs are peculiar in the way they specify cognate tRNA recogni-
tion. While major identity elements in tRNA for recognition by
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Figure 1
Structural organization of mitochondrial TyrRSs compared with their homologues
in the three domains of life and in mimivirus. Each structural domain is displayed in
a different colour. Abbreviations are MTS, mitochondrial target sequence; N-core
and C-core, N and C parts of the catalytic domain, respectively; CP1, connective
peptide; -ACB, -helical anticodon-binding domain; C-W/Y, C-terminal domain
homologue to TrpRS; S4-like, ribosomal protein S4-like domain; extra-Ct,
additional C-terminal domain. The full-length version of human mt-TyrRS (458
residues) was overexpressed without the MTS extension (arrow 1) and the
truncated enzyme (356 residues) was overexpressed after further removal of the
C-terminal S4-like domain (arrow 2). Notice that only one mimivirus is known; it
codes for a TyrRS that resembles archaeal TyrRSs (Abergel et al., 2005).
aaRSs have mostly been conserved in evolution (Giege´ et al., 1998),
this is not the case in the tyrosine system. The major determinant,
namely base pair N1–N72 at the top of the tRNATyr-accepting branch,
is G–C in bacteria/mitochondria but C–G in archaea/eukarya.
Moreover, for reasons that are still unclear, base pair G1–C72 has lost
its functional role in human mitochondria and most likely also in
other vertebrate mitochondria (Bonnefond, Frugier et al., 2005). To
date, structural knowledge of mitochondrial aaRSs is limited to only
two enzymes, namely TyrRS from Neurospora crassa (Paukstelis et
al., 2005) and bovine SerRS (Chimnaronk et al., 2004). Our interest in
mitochondrial aaRSs (Bonnefond, Fender et al., 2005) also stems
from the structural and functional peculiarities of mitochondrial
tRNA aminoacylation systems compared with their cytoplasmic
homologues (Sissler et al., 2005) and, in the particular case of human
mitochondria, from the correlations between pathologies and defects
in the translational machinery (Florentz et al., 2003; Jacobs & Turn-
bull, 2005). For all these reasons, we focused our attention on TyrRS
from Homo sapiens mitochondria, a protein that shows 37%
sequence identity with the most closely related TyrRS of known
structure, namely that from B. stearothermophilus. Here, we report
the crystallization and X-ray crystallographic studies of this human
TyrRS in its full-length (human mt-TyrRS) and C-terminally trun-
cated (human mt-TyrRS-S4) versions.
2. Material and methods
2.1. Cloning, overproduction and protein characterization
Two forms of human mt-TyrRS were produced: the full-length
protein and a truncated form lacking the S4-like domain (Fig. 1). Full-
length TyrRS was cloned as described in Bonnefond, Fender et al.
(2005). The truncated version was cloned following the same proce-
dure using the pQE70-mt-TyrRS plasmid as PCR template (primers
were 50-ATG CGAGGATCC CAC TCG GGC GCT CAG GGG-30
and 50-GGTGGTAGATCTGTGATAAAGGGC TTG TGTACA
CC-30, with BamHI and BglII restriction sites in bold). The cloning
vector introduced a tetrapeptide (MRGS) and a His-tagged octa-
peptide (RSH6) at the N- and C-terminal extremities of the cloned
TyrRSs, respectively. The overproduction and purification procedures
were similar for both proteins and were adapted with minor modifi-
cations from Bonnefond, Fender et al. (2005). In brief, top10
Escherichia coli strains containing either pQE70-mt-TyrRS or
pQE70-mt-TyrRS-S4 were grown in LB medium at 310 K until an
OD600 of 0.7 was reached. Protein expressions were induced over-
night at 298 K with 500 mM IPTG. After centrifugation, cell pellets
were suspended in 25 ml buffer A [50 mM NaH2PO4 pH 8.0, 300 mM
NaCl, 5 mM dithioerythritol (DTE)] and sonicated six times for 45 s
on ice. Lysed cells were centrifuged at 35 000g for 30 min at 277 K
and the supernatants were loaded onto a 2 ml Ni–NTA column
(Qiagen). Proteins were eluted with an imidazole gradient (20–
500 mM). The pooled enzyme-containing fractions were dialyzed and
concentrated for 3 h at 277 K against buffer B (50 mM HEPES–
NaOH pH 6.7, 300 mM NaCl, 10 mM DTE) with 50% glycerol. Two
further dialyses for 2 h against buffer B with 10% glycerol and then
overnight against buffer B gently removed glycerol with minimal
volume change. About 5 mg (at 2–3 mg ml1) full-length or 25 mg
(at 6 mg ml1) truncated electrophoretically pure human mt-
TyrRSs were recovered from 1 l LB medium.
The protein particle weight and polydispersity were determined on
the basis of size-exclusion chromatography (SEC) and dynamic light-
scattering (DLS) measurements. SEC analyses were performed at
277 K on an analytical 15 ml Bio-Prep SE-100/17 column (Bio-Rad)
equilibrated in buffer B. The TyrRS elution volume was compared
with those of proteins of known molecular weights and hydrodynamic
radius. DLS analyses were performed at 293 K on 12 ml protein
samples at appropriate concentration using a DynaPro DP801
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Figure 2
Crystals and diffraction properties of human mt-TyrRS. (a) Needles of full-length mt-TyrRS grown in 2M ammonium sulfate pH 6.5, 10% glycerol, 0.1Mmagnesium sulfate.
(b) Prismatic crystals of truncated mt-TyrRS-S4 in 18%(w/v) PEG 4000, 120 mM ammonium acetate, 0.1M Tris–sodium citrate pH 5.6. (c) Bipyramidal crystals of mt-
TyrRS-S4 in 30%(w/v) PEG 4000, 0.2M ammonium acetate, 0.1M sodium acetate pH 4.6. The bars in (a), (b) and (c) correspond to 100 mm. (d) Diffraction pattern of a
bipyramidal crystal. The image consists of a 0.5 oscillation. The resolution at the corner and the edge of the ADSC Quantum Q210 detector is 2.0 and 2.6 A˚, respectively.
Reflections of the [00l] row (see indices) indicate the presence of a helicoidal fourfold axis along the c/c* direction.
instrument (Protein Solutions Inc.). Diffusion coefficients, particle
radii and weights were corrected for buffer viscosity and refractive
index. Other protein-characterization techniques (SDS–PAGE and
N-terminal sequencing) were performed using standard methods.
TyrRS activities were determined as described in Bonnefond, Fender
et al. (2005).
2.2. Protein crystallization and crystal analysis
Crystallization trials were set up at 293 K in 96-well plates
(Greiner) using a Mosquito robot (TTP LabTech Ltd). Sitting drops
of 600 nl–2 ml (1:1 to 4:1 mixtures of 3–6 mg ml1 protein in buffer B
and reservoir solutions) were equilibrated by vapour diffusion against
80 ml reservoir solution. Prefilled screens (Qiagen) were employed
with both full-length and truncated mt-TyrRS. Crystals of either
enzyme form grew in about two weeks. They were mounted in
cryoloops (Hampton Research), their mother liquor replaced with
Paratone (Hampton Research) and flash-frozen in a nitrogen stream.
Two data sets for truncated TyrRS were successfully collected to 3.2
and 2.7 A˚ resolution at 93 K on the ID14-EH4 or ID14-EH1 beam-
lines at ESRF, France equipped with an ADSC Quantum 315 or 210
CCD detectors, respectively. Data were processed with the HKL
package (Otwinowski & Minor, 1997).
3. Results and discussion
3.1. Purification, stability and crystallization of full-length human
mt-TyrRS
Purification of full-length human mt-TyrRS (103 kDa, 2  458
residues) resulted in pure and active protein (Bonnefond, Fender et
al., 2005). Migration of the pure protein on an SDS gel under redu-
cing conditions with DTE in the loading buffer revealed a single band
corresponding to the intact monomer, as confirmed by N-terminal
sequencing. DLS measurements indicated the protein to be poly-
disperse and gave a mean hydrodynamic radius of 54 A˚, in agreement
with the expectation that the enzyme forms an elongated dimer. This
enzyme has a tendency to aggregate and to lose its activity at
concentrations above 2 mg ml1.
Extensive crystallization assays, conducted with fresh protein
samples at 2 mg ml1, led to needle-like crystals (Fig. 2a) that
diffracted X-rays poorly. Their quality could not be improved.
Further assays with the enzyme complexed to E. coli tRNATyr (as
verified by DLS analysis) were also ineffective in producing crystals
suitable for structure determination. Similar observations were
reported for the mitochondrial TyrRS from N. crassa (Paukstelis et
al., 2005).
3.2. Towards high-quality crystals
As was performed with E. coli (Kobayashi et al., 2005), Staphylo-
coccus aureus (Qiu et al., 2001) and mitochondrial N. crassa TyrRSs
(Paukstelis et al., 2005), the C-terminal domain of human mt-TyrRS,
which is likely to be floppy, was removed. This domain, which is
analogous to ribosomal protein S4, was delimited by multiple
sequence alignment with bacterial TyrRSs and assigned as the 102 last
residues (Fig. 1). The truncated version therefore encompasses the
N-terminal catalytic domain and the anticodon-binding domain.
The purified truncated TyrRS migrates as a unique 40 kDa band on
SDS gel, activates tyrosine and charges E. coli tRNATyr. This protein
(2  356 residues) is monodisperse in DLS, with a mean hydro-
dynamic radius of 38 A˚, in agreement with a homodimeric structure.
This conclusion was confirmed by SEC analyses. Importantly, dele-
tion of the S4-like domain significantly increases the solubility of the
synthetase, which can now be concentrated up to 20 mg ml1, thus
opening new crystallization possibilities.
More than 600 different crystallization conditions were assayed
with human mt-TyrRS-S4, of which 40 gave crystals. Most of them
contained PEGs as the crystallizing agent. The largest crystals display
prismatic and bipyramidal morphologies (Figs. 2b and 2c). The better
diffracting bipyramidal crystals (Fig. 2c) grew reproducibly at pH 4.6
and in the presence of 30%(w/v) PEG 4000. By changing the
protein:precipitant ratio to 2:1, their dimensions were enlarged and
their diffraction limit extended from 3.2 to 2.7 A˚.
3.3. Preliminary X-ray data
Crystals of truncated TyrRS were analyzed using synchrotron
radiation. Statistics and other crystallographic data for the best
crystal are given in Table 1. Based on systematically absent reflec-
tions, the space group is either P43212 or P41212 (Fig. 2d). Analysis of
the solvent content performed with the CCP4 package (Collaborative
Computational Project, Number 4, 1994) gave a unique solution
consistent with one polypeptide chain (356 residues) per asymmetric
unit. Molecular-replacement (MR) trials were performed with the
CaspR MR webservice (Claude et al., 2004) using the structure of
E. coli TyrRS (PDB code 1wq3) and derived search models. In the
resolution range 3–15 A˚, space group P43212 gave a better solution
(correlation = 52%, R factor = 53%) than its enantiomorph P41212
(correlation = 46%, R factor = 56%). Notice that the subunits of the
biological dimer are related by the crystallographic twofold symmetry
axis. After rigid-body refinement, the MR solution led to an inter-
pretable electron-density map. Refinement of the model is in
progress.
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Table 1
X-ray analysis of a human mt-TyrRS-S4 crystal.
Data were collected from a bipyramidal crystal (see Fig. 2c); values in parentheses are for
the highest resolution shell.
Beamline ID14-1, ESRF
Wavelength (A˚) 0.934
Space group P43212
Unit-cell parameters (A˚) a = 78.8, c = 121.1
Crystal mosaicity () 0.7
Resolution range (A˚) 2.7–30 (2.7–2.8)
No. of observations 534152
No. of unique reflections 11044
Completeness (%) 99.9 (100)
Multiplicity 13.1 (13.3)
Rmerge† (%) 6.8 (37.2)
hI/(I)i 27.8 (4.9)
Matthews coefficient (A˚3 Da1) 2.4
Solvent content (%) 48
Asymmetric unit content 1 monomer
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ.
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